Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

C-RAD Showcases Industry-Leading Partnerships and Advanced SGRT Solutions at ASTRO 2024

C-Rad

C-RAD, a global leader in surface guided radiation therapy (SGRT), is proud to announce its participation in the 66th American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place from September 29 to October 2, 2024. At Booth 1403, C-RAD will present its most extensive interoperability portfolio, featuring interfaces with leading Linac and CT vendors, alongside advancements in proton therapy.

C-RAD continues to advance its capabilities in proton therapy, having recently validated two additional Particle Therapy Systems for respiratory gating with Catalyst+ PT. These achievements bolster their position as a leader in this high-precision treatment modality, further solidifying its role as a trusted partner for healthcare providers around the world.

C-RAD is continuing their collaborative journey with RaySearch Laboratories AB (publ), aiming to jointly develop innovative solutions and products to enhance the quality of radiation therapy, building on the foundation announced at ESTRO this year.

As part of this ongoing collaboration, experts from both teams will showcase recent developments and exciting new clinical scenarios at the RaySearch and C-RAD booths.

In line with its strong partnership with Accuray, C-RAD will highlight Catalyst+ HD at Accuray’s Exchange Academy, a key feature of Accuray’s program at ASTRO. This collaboration underscores the integration of C-RAD’s advanced technologies with Accuray’s systems, showcasing the latest innovations and clinical benefits aimed at improving patient outcomes in radiation therapy.

“We are thrilled to present our most extensive SGRT interoperability portfolio at ASTRO 2024, including VitalHold™ for Accuray Radixact®, and to demonstrate our commitment to pushing the boundaries of SGRT,” said Cecilia de Leeuw, President and CEO of C-RAD. “We are excited about the future of our partnerships as we continue to innovate and drive advancements in cancer treatment.”

C-RAD will also participate in the ASRT Radiation Therapy Conference, in conjunction with ASTRO, to engage with radiation therapy professionals on the latest in SGRT technologies.

About C-RAD


C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD. Inspiring excellence in cancer treatment.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit http://www.c-rad.com

Attachments


C-RAD Showcases Industry-Leading Partnerships and Advanced SGRT Solutions at ASTRO 2024

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.